Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genkyotex SA

Small molecule NOX inhibitors for diabetic neuropathy

This article was originally published in Start Up

Executive Summary

Genkyotex SA, named after Geneva, Kyoto and Texas, the locations of three of the academic founders, is developing small molecules that specifically inhibit NOX enzymes. Its lead product is a selective and orally available NOX1/4 inhibitor and is a first-in-class molecule. The initial target for this product is diabetic nephropathy, but the company believes it has potential in a range of other disorders in areas of unmet medical need, including in atherosclerosis, ophthalmological diseases involving angiogenesis such as retinopathy and wet age-related macular degeneration, and fibrosis. The agent has orphan drug status in the EU and the US for the treatment of idiopathic pulmonary fibrosis.

You may also be interested in...



GenKyoTex, PsiOxus Raise VC Funding In Europe To Reach Phase II POC

GenKyoTex's first-in-class NOX inhibitors and PsiOxus's oncolytic viruses attract funding from European VCs to cross "death valley."

Gadeta BV: Using T-Cells To Target Metabolic Dysregulation In Cancer

Emerging Company Profile: Gadeta, a Dutch spin-out from University Medical Centre Utrecht, launched earlier this year to develop modified T-cell-based therapies that target metabolic dysregulation in solid and hematological malignancies.

PeptiMimesis

PeptiMimesis is developing first-in-class transmembrane therapeutic peptides with potential in immuno-oncology, oncology and immune diseases. Its technology is based on research showing that targeting the transmembrane domain using a single peptide can block several of the processes involved in the development of cancer by disrupting dimerization of target receptors, impairing the formation of receptor complexes and indirectly blocking the subsequent signaling pathways

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

GB150348

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel